BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Treatment
26929 results:

  • 1. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
    Wang X; Yang Y
    Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
    Salim N; Tumanova K; Popodko A; Libson E
    JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. treatment and prognosis study of spontaneous rupture hemorrhage in hepatocellular carcinoma: Recommendations for adding the A1 stage to the BCLC staging system.
    Ni Q; Jia H; Zhang Y; Lu J; Chang H
    Cancer Med; 2024 May; 13(10):e6952. PubMed ID: 38752672
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
    Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
    J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
    Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
    PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment.
    Luo J; Yuan M; Li S; Chen L; Zhou M; Li H; Bai X; Zhang Z; Zeng W; Sun X; Zhang Q; Chen Y; Zhou L
    Rev Inst Med Trop Sao Paulo; 2024; 66():e27. PubMed ID: 38747848
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Rice bran arabinoxylan compound as a natural product for cancer treatment - an evidence-based assessment of the effects and mechanisms.
    Ooi SL; Micalos PS; Kim J; Pak SC
    Pharm Biol; 2024 Dec; 62(1):367-393. PubMed ID: 38745507
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.
    Xiao Y; Deng W; Luo L; Zhu G; Xie J; Liu Y; Wan R; Wen W; Hu Z; Shan R
    BMC Cancer; 2024 May; 24(1):588. PubMed ID: 38745113
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
    Wang Y; Lu BH; Gao Y; Liu YX; Hu MM; Che NY; Lin HF; Li HX; Zhang HM; Zhang TM
    Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):419-427. PubMed ID: 38742355
    [No Abstract]    [Full Text] [Related]  

  • 11. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
    Kasuga R; Taniki N; Chu PS; Tamura M; Tabuchi T; Yamaguchi A; Hayatsu S; Koizumi J; Ojiro K; Hoshi H; Kaneko F; Morikawa R; Noguchi F; Yamataka K; Usui S; Ebinuma H; Itano O; Hasegawa Y; Abe Y; Kitago M; Inoue M; Nakatsuka S; Jinzaki M; Kitagawa Y; Kanai T; Nakamoto N
    Sci Rep; 2024 May; 14(1):10896. PubMed ID: 38740983
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
    Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
    JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.
    Liu K; Li Q; Lu X; Fan X; Yang Y; Xie W; Kang J; Sun S; Zhao J
    Pharm Biol; 2024 Dec; 62(1):404-422. PubMed ID: 38739082
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Curative effect of percutaneous microwave ablation therapy on hepatocellular carcinoma survival: a 15-year real-world study].
    Luo YC; Lang ML; Cai WJ; Han ZY; Liu FY; Cheng ZG; Yu XL; Dou JP; Li X; Tan SL; Dong XJ; Liang P; Yu J
    Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):332-339. PubMed ID: 38733188
    [No Abstract]    [Full Text] [Related]  

  • 15. Enrichment and Evaluation of Antitumor Properties of Total Flavonoids from
    Yang S; Chu G; Wu J; Zhang G; Du L; Lin R
    Molecules; 2024 Apr; 29(9):. PubMed ID: 38731467
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
    PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
    Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
    Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Novel Inositol 1,4,5-Trisphosphate Receptor Inhibitor Antagonizes Hepatic Stellate Cell Activation: A Potential Drug to Treat liver Fibrosis.
    Smith-Cortinez N; Heegsma J; Podunavac M; Zakarian A; Cardenas JC; Faber KN
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727301
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Malnutrition as an unfavorable prognostic factor after surgical treatment for metastatic colorectal cancer.
    Skroński M; Olszewska N; Nyckowski P; Ukleja A; Lisowska J; Słodkowski M; Szczygieł B
    Pol Przegl Chir; 2024 Mar; 96(3):1-8. PubMed ID: 38721641
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. In vitro study on anti-proliferative and anti-cancer activity of picrosides in triple-negative breast cancer.
    Soni D; Wahi D; Verma S
    Med Oncol; 2024 May; 41(6):143. PubMed ID: 38717628
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1347.